ID   MKN74
AC   CVCL_2791
SY   MKN-74; MKN 74
DR   BTO; BTO:0002383
DR   CLO; CLO_0050798
DR   EFO; EFO_0002834
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN01821701
DR   BioSample; SAMN03473122
DR   BioSample; SAMN10987828
DR   cancercelllines; CVCL_2791
DR   Cell_Model_Passport; SIDM00248
DR   CGH-DB; 121-1
DR   CGH-DB; 9023-4
DR   ChEMBL-Cells; CHEMBL3307287
DR   ChEMBL-Targets; CHEMBL614048
DR   CLS; 300490
DR   Cosmic; 685597
DR   Cosmic; 801340
DR   Cosmic; 848148
DR   Cosmic; 848372
DR   Cosmic; 873712
DR   Cosmic; 877043
DR   Cosmic; 887253
DR   Cosmic; 888828
DR   Cosmic; 897536
DR   Cosmic; 918498
DR   Cosmic; 922695
DR   Cosmic; 926115
DR   Cosmic; 983728
DR   Cosmic; 1007603
DR   Cosmic; 1067209
DR   Cosmic; 1090462
DR   Cosmic; 1093300
DR   Cosmic; 1122338
DR   Cosmic; 1187285
DR   Cosmic; 1223590
DR   Cosmic; 1436027
DR   Cosmic; 1460709
DR   Cosmic; 1477424
DR   Cosmic; 1518244
DR   Cosmic; 2484974
DR   Cosmic; 2807635
DR   DepMap; ACH-000758
DR   EGA; EGAS00001000610
DR   GEO; GSM562418
DR   GEO; GSM827533
DR   GEO; GSM844609
DR   GEO; GSM887325
DR   GEO; GSM888401
DR   GEO; GSM1374682
DR   IARC_TP53; 21642
DR   IARC_TP53; 30196
DR   JCRB; JCRB0255
DR   KCLB; 80104
DR   LiGeA; CCLE_606
DR   LINCS_LDP; LCL-1536
DR   PharmacoDB; MKN74_940_2019
DR   Progenetix; CVCL_2791
DR   PubChem_Cell_line; CVCL_2791
DR   RCB; RCB1002
DR   Wikidata; Q54905833
RX   CelloPub=CLPUB00581;
RX   CelloPub=CLPUB00584;
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RX   PubMed=1370612;
RX   PubMed=1933850;
RX   PubMed=3962675;
RX   PubMed=6862145;
RX   PubMed=9290701;
RX   PubMed=11107048;
RX   PubMed=11314020;
RX   PubMed=15723654;
RX   PubMed=15767549;
RX   PubMed=15900046;
RX   PubMed=20215515;
RX   PubMed=22336246;
RX   PubMed=22460905;
RX   PubMed=24587255;
RX   PubMed=24807215;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=29435981;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: JFCR45 cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 42-46 hours (PubMed=3962675); 44 hours (PubMed=29435981); 46-49 hours (CelloPub=CLPUB00584).
CC   HLA typing: A*31:01,31:01; B*51:01,51:01; C*03:04,03:04; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=25960936).
CC   HLA typing: A*31:01,31:01; B*51:01,51:01; C*03:04,03:04 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Leu (c.751A>C); ClinVar=VCV000182937; Zygosity=Unspecified (PubMed=1370612; PubMed=15900046).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=88.48%; East Asian, South=9.79%; South Asian=0.44%; European, North=0%; European, South=1.29% (PubMed=30894373).
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): CLS; JCRB; KCLB; PubMed=25877200; RCB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D12S391: 18,21
ST   D13S317: 11
ST   D16S539: 9,11
ST   D18S51: 12
ST   D19S433: 13,15.2
ST   D21S11: 32.2,33.2 (CLS)
ST   D21S11: 32.2 (PubMed=25877200)
ST   D2S1338: 18,23
ST   D3S1358: 16
ST   D5S818: 11
ST   D6S1043: 13
ST   D7S820: 9
ST   D8S1179: 11,16
ST   FGA: 23
ST   Penta D: 9
ST   Penta E: 11,14 (CLS)
ST   Penta E: 11,14,15 (PubMed=25877200)
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 16,20
DI   NCIt; C5473; Gastric tubular adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   37Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   CelloPub=CLPUB00581;
RA   Hojo H.;
RT   "Establishment of cultured cell lines of human stomach cancer origin
RT   and their morphological characteristics.";
RL   Niigata Igakkai Zasshi 91:737-763(1977).
//
RX   CelloPub=CLPUB00584;
RA   Motoyama T., Hojo H., Suzuki T., Oboshi S.;
RT   "Evaluation of the regrowth assay method as an in vitro drug sensitivity
RT   test and its application to cultured human gastric cancer cell lines.";
RL   Acta Med. Biol. 27:49-63(1979).
//
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RA   Sekiguchi M., Suzuki T.;
RT   "Gastric tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York (1994).
//
RX   PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0;
RA   Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O.,
RA   Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.;
RT   "Missense mutations and a deletion of the p53 gene in human gastric
RT   cancer.";
RL   Biochem. Biophys. Res. Commun. 182:215-223(1992).
//
RX   PubMed=1933850;
RA   Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S.,
RA   Nakatani K., Nakano H., Sugimura T., Terada M.;
RT   "p53 gene mutations in gastric cancer metastases and in gastric cancer
RT   cell lines derived from metastases.";
RL   Cancer Res. 51:5800-5805(1991).
//
RX   PubMed=3962675; DOI=10.1111/j.1440-1827.1986.tb01461.x;
RA   Motoyama T., Hojo H., Watanabe H.;
RT   "Comparison of seven cell lines derived from human gastric
RT   carcinomas.";
RL   Acta Pathol. Jpn. 36:65-83(1986).
//
RX   PubMed=6862145; DOI=10.20772/cancersci1959.74.2_240;
RA   Naito S., Inoue S., Kinjo M., Tanaka K.;
RT   "Thromboplastic and fibrinolytic activities of cultured human gastric
RT   cancer cell lines.";
RL   Gann 74:240-247(1983).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x;
RA   Yokozaki H.;
RT   "Molecular characteristics of eight gastric cancer cell lines
RT   established in Japan.";
RL   Pathol. Int. 50:767-777(2000).
//
RX   PubMed=11314020; DOI=10.1038/sj.onc.1204160;
RA   Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T.,
RA   Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.;
RT   "Alpha-fetoprotein producing gastric cancer lacks transcription factor
RT   ATBF1.";
RL   Oncogene 20:869-873(2001).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D.-X., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24587255; DOI=10.1371/journal.pone.0090155;
RA   Endo F., Nishizuka S.S., Kume K., Ishida K., Katagiri H., Ishida K.,
RA   Sato K., Iwaya T., Koeda K., Wakabayashi G.;
RT   "A compensatory role of NF-kappaB to p53 in response to 5-FU-based
RT   chemotherapy for gastric cancer cell lines.";
RL   PLoS ONE 9:E90155-E90155(2014).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//